ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Johnson & Johnson, Novartis and Azidus Brasil side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Johnson & Johnson×Novartis×Azidus Brasil×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Johnson & JohnsonNovartisAzidus Brasil
studies on the registry3,7093,90080
open to participants now1462125
phase 3 studies under way95944
reach primary completion within a year881251
programswith a study of their own in two years56+4 named only77+7 named onlynone read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJohnson & JohnsonNovartisAzidus Brasil
Phase 1

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
–
Phase 2

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
–
Phase 3

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
–
Approved, new studies

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%
–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Johnson & Johnson26 readouts · 8 phase 3

Johnson & Johnson, Nov ’26: 1 program whose next study reaches primary completion

  1. JNJ-95597528phase 2 · Nov 19 · NCT07230860

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · Jan 4 · NCT05397496
  2. opnurasibphase 3 · Jan 25 · NCT04699188
  3. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 2 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
Azidus Brasil0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 5

Azidus Brasil

No programs read for this company.

Where they overlap

Conditions where at least two of them have programs: 25 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionJohnson & JohnsonNovartisAzidus Brasil
Prostatic Neoplasms2 of 3 · compare here

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

–
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Lymphoma, Non-Hodgkin2 of 3 · compare here

Novartis in Lymphoma, Non-Hodgkin: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Non-Hodgkin in search

–
Breast Neoplasms2 of 3 · compare here

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

–
Multiple Myeloma2 of 3 · compare here

Johnson & Johnson in Multiple Myeloma: 6 programs

  1. ramantamigphase 3
  2. fludarabinephase 2
  3. JNJ-102299639phase 1
  4. JNJ-87562761phase 1
  5. teclistamabapproved, new study

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Multiple Myeloma in search

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

–
Neoplasms2 of 3 · compare here

Novartis in Neoplasms: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

–
Arthritis, Psoriatic2 of 3 · compare here

Johnson & Johnson in Arthritis, Psoriatic: 4 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. JNJ-88545223phase 2
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Arthritis, Psoriatic in search

Novartis in Arthritis, Psoriatic: 2 programs

  1. DDY391phase 2
  2. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Psoriatic in search

–
Arthritis, Rheumatoid2 of 3 · compare here

Johnson & Johnson in Arthritis, Rheumatoid: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Arthritis, Rheumatoid in search

Novartis in Arthritis, Rheumatoid: 5 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  4. DKB903phase 1
  5. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Rheumatoid in search

–
Dermatitis, Atopic2 of 3 · compare here

Johnson & Johnson in Dermatitis, Atopic: 2 programs

  1. JNJ-95597528phase 2
  2. JNJ-95475939phase 2

Their studies: Johnson & Johnson’s studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

–
Alzheimer Disease2 of 3 · compare here

Johnson & Johnson in Alzheimer Disease: 3 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. JNJ-64042056phase 2

Their studies: Johnson & Johnson’s studies of Alzheimer Disease in search

Novartis in Alzheimer Disease: 2 programs

  1. Oligonucleotides, Antisensephase 2
  2. VHB937phase 2

Their studies: Novartis’s studies of Alzheimer Disease in search

–
Colorectal Neoplasms2 of 3 · compare here

Johnson & Johnson in Colorectal Neoplasms: 3 programs

  1. amivantamabphase 3
  2. olomorasibphase 2
  3. JNJ-89402638phase 1

Their studies: Johnson & Johnson’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

–
Psoriasis2 of 3 · compare here

Johnson & Johnson in Psoriasis: 3 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Psoriasis in search

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

–

Show all 25

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Johnson & Johnson 33 of 56 · Novartis 56 of 77 · Azidus Brasil 0 of 0 programs (34 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4, Novartis: 7).